Enlaza Therapeutics

About Enlaza Therapeutics

Enlaza Therapeutics is pioneering the development of first-in-class covalent protein therapeutics to transform the treatment of cancer and other serious diseases. Their mission is to create a groundbreaking new class of protein therapeutics using their proprietary War-Lock™ technology, which enables the generation of highly selective biologic drugs with improved efficacy and safety profiles for patients.

Products & Services

War-Lock™ Biologics:A novel class of covalent protein therapeutics engineered to irreversibly bind to disease-related targets, improving efficiency, target modulation, and reducing the need for continuous systemic exposure. These biologics aim to provide safer and more effective therapies with sustained target occupancy and minimal healthy tissue exposure.

Specialties

Covalent Protein Therapeutics War-Lock™ Technology Synthetic Biology Oncology Biologic Drug Engineering Unnatural Amino Acids Integration

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 100000000 MR: - FA: $100 million FAN: 100000000	D: 2024-04-30 FD: 2024-04-30	10 investors

Series A Latest

2024-04-30

$100.0M

10 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Sergio Duron

Co-Founder and Chief Executive Officer

S

Sanford Madigan

Co-Founder, President and Chief Business Officer

A

Analeah Heidt

Chief Scientific Officer

J

Joseph Woolery

Senior Vice President, Head of Clinical Development

D

Danny Beck

Vice President, Business Development

P

Patrick Burke

Vice President, Chemistry

View 15 more team members with Pro

Unlock Full Team Directory

Recent News